Last reviewed · How we verify
Peginterferon-alfa 2a and tenofovir
Peginterferon-alfa 2a and tenofovir is a Interferon and nucleotide reverse transcriptase inhibitor Small molecule drug developed by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). It is currently in Phase 3 development for Chronic hepatitis B, Chronic hepatitis C. Also known as: Hepatitis B, PEGASYS, Viread, tenofovir.
Peginterferon-alfa 2a is an interferon that modulates the immune system to treat viral infections, while tenofovir is a nucleotide reverse transcriptase inhibitor that blocks viral replication.
Peginterferon-alfa 2a is an interferon that modulates the immune system to treat viral infections, while tenofovir is a nucleotide reverse transcriptase inhibitor that blocks viral replication. Used for Chronic hepatitis B, Chronic hepatitis C.
At a glance
| Generic name | Peginterferon-alfa 2a and tenofovir |
|---|---|
| Also known as | Hepatitis B, PEGASYS, Viread, tenofovir |
| Sponsor | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
| Drug class | Interferon and nucleotide reverse transcriptase inhibitor |
| Target | Interferon receptor, reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
Peginterferon-alfa 2a works by stimulating the body's immune response to fight viral infections, while tenofovir inhibits the replication of viral DNA by blocking the action of reverse transcriptase. This combination of mechanisms makes peginterferon-alfa 2a and tenofovir effective against a range of viral infections.
Approved indications
- Chronic hepatitis B
- Chronic hepatitis C
Common side effects
- Fatigue
- Headache
- Nausea
- Diarrhea
- Abdominal pain
Key clinical trials
- Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV) (PHASE2)
- A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection (PHASE2)
- A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus Infection (PHASE2)
- A Study of Hepalatide Combined With TAF and PEG-IFN as Finite Treatment of Chronic Hepatitis B Patients (PHASE2)
- A Study of JNJ-73763989, JNJ-56136379, Nucleos(t)Ide Analogs, and Pegylated Interferon Alpha-2a in Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection (PHASE2)
- A Study of JNJ-73763989, Pegylated Interferon Alpha-2a and Nucleos(t)Ide Analogs in Participants With Chronic Hepatitis B Virus Infection (PHASE2)
- Combination Therapy of Pegylated Interferon Alfa-2a and Tenofovir Versus Tenofovir Monotherapy in Chronic Hepatitis B (PHASE3)
- Effects of Anti-HIV Therapy on Treatment for Hepatitis C in HCV/HIV Infected Adults (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Peginterferon-alfa 2a and tenofovir CI brief — competitive landscape report
- Peginterferon-alfa 2a and tenofovir updates RSS · CI watch RSS
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) portfolio CI
Frequently asked questions about Peginterferon-alfa 2a and tenofovir
What is Peginterferon-alfa 2a and tenofovir?
How does Peginterferon-alfa 2a and tenofovir work?
What is Peginterferon-alfa 2a and tenofovir used for?
Who makes Peginterferon-alfa 2a and tenofovir?
Is Peginterferon-alfa 2a and tenofovir also known as anything else?
What drug class is Peginterferon-alfa 2a and tenofovir in?
What development phase is Peginterferon-alfa 2a and tenofovir in?
What are the side effects of Peginterferon-alfa 2a and tenofovir?
What does Peginterferon-alfa 2a and tenofovir target?
Related
- Drug class: All Interferon and nucleotide reverse transcriptase inhibitor drugs
- Target: All drugs targeting Interferon receptor, reverse transcriptase
- Manufacturer: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) — full pipeline
- Therapeutic area: All drugs in Infectious Diseases
- Indication: Drugs for Chronic hepatitis B
- Indication: Drugs for Chronic hepatitis C
- Also known as: Hepatitis B, PEGASYS, Viread, tenofovir
- Compare: Peginterferon-alfa 2a and tenofovir vs similar drugs
- Pricing: Peginterferon-alfa 2a and tenofovir cost, discount & access